INTRODUCTION
Pancreatic adenocarcinoma (PC) is the 12th most commonly diagnosed cancer in the United States but is the 3rd leading cause of cancer death; the national 5-year survival rate is 8.2%.
1 Although most diagnoses of PC are considered sporadic, about 10% of diagnoses are attributed to hereditary causes. 2 Factors that increase the likelihood of a hereditary cause for PC include a personal history of other syndrome-related cancers, a family history of PC or related cancers, and Ashkenazi Jewish ancestry. 3 Germline mutations in APC, ATM, BRCA1, BRCA2, CDKN2A, the mismatch repair genes (MLH1, MSH2/EPCAM, MSH6, and PMS2), PALB2, STK11, and TP53 have been associated with an increased risk for PC. [4] [5] [6] [7] [8] [9] [10] [11] [12] Historically, individuals with PC have been seldom referred for genetic counseling for several reasons. First, each of these genes alone is responsible for a small proportion of hereditary PC susceptibility, so the yield from single gene testing was considered low. Second, the results from genetic testing would not have altered PC cancer treatment. Third, given the poor survival rates of individuals with PC, future cancer surveillance or prevention was not justified. Fourth, the association between PC and hereditary cancer syndromes has historically been underrecognized by many health care providers.
With the advent of multigene panel tests, the ability to quickly and cost-effectively analyze all of the genes associated with PC risk has increased the yield of genetic testing. As personalized medicine advances, germline gene mutation status is increasingly important in cancer treatment. For example, individuals with mutations in the BRCA1/2 pathway may benefit from PARP inhibitor treatment or platinum-based chemotherapy regimens, and individuals with mismatch repair gene mutations can be prescribed anti-PD1 immunotherapy. [13] [14] [15] These advances indicate that genetic testing is becoming a more integral part of care for individuals with PC and increase the need for health care providers to recognize the importance of considering genetic testing for individuals with PC.
Guidelines for genetic testing in an individual with PC, however, are still limited. For example, using National Comprehensive Cancer Network (NCCN) guidelines for Lynch syndrome (LS), individuals with PC who have a personal history of colon cancer would qualify for genetic testing because they meet the Bethesda guidelines due to the presence of colon cancer and a synchronous or metachronous Lynch-related cancer, but individuals with a personal history of any other Lynch-related cancer or a family history of Lynch-related cancers would not. 16 The NCCN genetic testing guidelines for hereditary breast and ovarian cancer (HBOC) only account for family history for an individual with PC. 17 An individual with PC who has a personal history of cancer may meet testing criteria if his or her previous cancer history alone is sufficient (eg, a woman with ovarian cancer or a man with breast cancer), but their PC diagnosis does not contribute to their eligibility. Individuals with PC who have no personal history of other cancers only meet NCCN testing criteria if they have 1 family member with breast cancer before age 50 or ovarian cancer or if they have 2 family members with breast cancer at any age, PC, or prostate cancer (Gleason score 7).
Because the genes associated with PC to date are all more strongly associated with other cancer types, personal and family history of other cancers is relevant to genetic risk assessment for individuals with PC. The primary aim of this study was to determine the prevalence of germline mutations in cancer susceptibility genes in individuals with PC and a personal history of other HBOC-and LSrelated cancers. Our purpose in studying this selected population was to determine whether previous cancer history would enrich the yield of genetic testing compared with an unselected PC population or a PC population that was selected based on family history alone. This study has public health significance in that identifying families with a genetic predisposition to PC may help increase early detection of the disease and allow for more effective personalized cancer treatment.
PATIENTS AND METHODS
Participants were selected from the University of Pittsburgh's Pancreatic Adenocarcinoma Gene Environment Risk (PAGER) study, which has been described previously. 18 Any PAGER participant with a diagnosis of PC who was enrolled between February 2004 and June 2015 was considered potentially eligible for this study. Data for these participants were reviewed to identify individuals with a personal history of another HBOC-related cancer (breast, ovarian, prostate, and melanoma) or another Bethesda-designated LS-related cancer (colorectal, endometrial, stomach, ovarian, ureter, renal pelvis, biliary tract, brain, and small bowel, as well as sebaceous gland adenomas and keratoacanthomas). Information about previous clinical genetic testing was obtained.
Eligible participants for whom banked DNA was available underwent a multigene cancer panel (the research panel) unless 1) previous clinical testing had already identified a mutation in a PC-susceptibility gene or 2) previous clinical multigene cancer panel testing failed to identify any mutations. Some participants' research panel testing included sequencing of 29 genes (APC, ATM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, EPCAM, MEN1, MET, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PALLD, PMS2, PTCH1, PTEN, RAD51C, RET, SMAD4, STK11, TP53, and VHL) as described previously. 19 In these tests, CHEK2 analysis was limited to the c.1100delC mutation and PMS2 sequencing excluded exons 12-15. Participants whose research panel testing was performed later included complete sequencing of CHEK2 and PMS2, as well as sequencing of 5 other genes (BARD1, FANCC, MRE11A, NF1, and RAD50), for a total of 34 genes, following an expansion of the laboratory's panel; other than this difference, the 2 panels were validated to be analytically equivalent. Variants were classified using a framework (Sherloc) based on the American College of Medical Genetics 2015 guidelines. 20, 21 Fisher's exact test was used to evaluate differences between mutation carriers and other individuals.
RESULTS
One hundred forty-nine of 1296 individuals with PC had at least 1 other HBOC-or LS-related cancer (11.5%). Twenty-seven individuals had a history of more than 1 related cancer. All HBOC-and LS-related cancer types were observed except for biliary tract and brain cancers. Most participants were female (57.0%) and white (96.0%). The majority of individuals did not report Ashkenazi Jewish ancestry (98%). The mean age of first syndrome-related cancer was 59.9 years (range, 14-88 years). The mean age of PC diagnosis was 71.2 years (range, 42-96 years). For all study participants but 1, PC was the final cancer diagnosis. Most individuals (103) had a previous history of only 1 other cancer; 1 individual was diagnosed with a second cancer after PC. Thirty participants had 2 previous cancers, 7 participants had 3 previous cancers, 3 participants each had 4 and 5 previous cancers, and 1 participant had 6 previous cancers. One participant had 2 primary PC diagnoses, which were his third and fifth cancer diagnoses. Table 1 provides the participant characteristics for the study.
Original Article
Nine participants had a mutation identified in a PCsusceptibility gene through previous clinical genetic testing. Ten participants had previously undergone clinical multigene panel testing with no mutations detected. Two participants had previously undergone clinical BRCA1 and BRCA2 testing with no mutations detected and had no available DNA for further testing. One participant did not have clinical genetic testing, but was known to be an obligate BRCA2 mutation carrier. Of the remaining 127 participants, DNA was available for 102 individuals, for whom the research panel was performed; 22 participants' testing included analysis of 29 genes, and 80 participants' testing included analysis of 34 genes. Genetic mutation status was therefore known for 124 of 149 individuals with PC and another HBOC-or LS-related cancer. In order not to overestimate mutation prevalence for the total population, calculations were also performed assuming the 25 individuals for whom DNA was not available had negative genetic testing. Figure 1 provides a study flowchart.
Twenty-two of 124 individuals with PC and a history of at least 1 other HBOC-or LS-related cancer who underwent genetic testing had a mutation identified in a gene associated with PC susceptibility (17.7%); this number equates to 14.8% of all individuals, including the 25 who did not have testing (22/149). Mutations were identified in ATM (4), BRCA1 (2), BRCA2 (7), CDKN2A (1), MLH1 (1), MSH2 (1), MSH6 (2), PALB2 (2), and TP53 (2). An MSH6 mutation carrier also had a mutation identified in BRIP1, a gene that has not been associated with PC risk. All mutation carriers were white, and none reported Ashkenazi Jewish ancestry. Table 2 provides a description of PC-gene mutation carriers.
Six other individuals had a mutation identified in at least 1 gene that has not been previously associated with PC, including BRIP1, MUTYH, and CHEK2. Thirty-one individuals had no mutations detected but were found to have at least 1 variant of uncertain significance. Sixty-five individuals had no mutations or variants of uncertain significance reported. Supplemental Table 1 (see online supporting information) provides a description of study participants who do not carry a mutation in a PC-related gene. Table 3 provides a breakdown of results by syndrome type.
Because prostate cancer is a common cancer that has only a loose association with currently identified hereditary cancer syndromes, we also calculated the data excluding 38 men whose only other syndrome-related cancer diagnosis was prostate cancer. Twenty-one of 93 tested individuals in this subset of our cohort had a mutation identified in a gene associated with PC risk (22.6%); 21 of 111 of the total subset had a mutation (18.9%). Four individuals had a mutation identified in a non-PC gene.
Forty-seven individuals in our cohort had a history of LS-related malignancies, 37 of whom underwent testing. Eleven individuals had a mutation identified in a PC gene (23.4% of the total group, 29.7% of the tested group); 4 individuals had a mutation in a non-PC gene.
Information about tumor microsatellite instability was available for 22 of the 47 individuals with LS-related cancers, either through mismatch repair immunohistochemistry (IHC) studies (21) or PCR testing (1). Eighteen individuals had tumors that were deemed microsatellite stable (1 by PCR and 17 with intact mismatch repair IHC expression); 1 of these participants had a germline MSH6 mutation, and 3 participants did not have DNA available for testing. Four individuals had abnormal IHC results; 2 of these participants had germline mutations that were concordant with their IHC results, 1 individual had negative germline testing but was strongly suspected to have an unidentified germline mutation based on personal and family history, and 1 individual had no DNA available for testing. Results from tumor testing was not found to be a significant predictor of a germline mismatch repair gene mutation (P 5 .056). PREMM5 scores were calculated for the 47 individuals with LS-related cancers using their personal cancer history and the information available about LS-related cancers in first-degree relatives. Thirty-three individuals had at least a 2.5% predicted probability of carrying a mismatch repair gene mutation, which is the risk deemed appropriate for referral for genetic evaluation by the model creators. 22 Fourteen individuals had a predicted probability of at least 5%, which is the risk deemed appropriate for consideration of genetic testing by NCCN.
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PREMM5 risk calculations were not found to be a significant predictor of a germline mismatch repair mutation when using either the 2.5% cutoff (P 5 .302) or the 5% cutoff (P 5 .073), nor were they a predictor of carrying a mutation in any PC-related gene (P 5 1.000 for 2.5% and P 5 .710 for 5%).
HBOC-related cancers were reported in 124 individuals in our cohort, 106 of whom had testing. Sixteen individuals had a mutation identified in a PC-related gene (12.9% of the total group, 15.1% of the tested group); 5 individuals had a mutation in a non-PC-related gene. Excluding prostate cancer, 15 of 81 individuals had a mutation in a PC-related gene (18.5% of total, 21.4% of tested); 2 individuals in this group had a mutation in a non-PC related gene. Figure 2 provides the percentages of individuals with mutations by syndrome type.
The likelihood of finding a mutation was highest in individuals who had a history of male breast, small bowel, and renal pelvis cancers and sebaceous neoplasms (100%), although the number of these individuals was small. The likelihood of finding a mutation was lowest in individuals with gastric cancer (0/1) and not surprisingly, men with prostate cancer (2.7%). Table 4 provides result percentages by cancer type.
The likelihood of identifying a mutation was not significantly different based on sex (P 5 .208), smoking status (P 5 .250), age of first cancer diagnosis before or after age 50 (P 5 .386), PC stage (P 5 .062), age of PC diagnosis before or after age 60 (P 5 .566), or having a firstdegree relative with an HBOC-or LS-related cancer (P 5 .357). Individuals with more than 1 prior cancer diagnosis were significantly more likely to have a mutation than Original Article individuals who only had 1 prior cancer (P 5 .001). Interestingly, obese individuals were significantly more likely to have a mutation than individuals with a body mass index of less than 30 (P < .001). Not surprisingly, individuals who had clinical testing were significantly more likely to have a mutation identified than individuals who had testing with the research panel (P 5 .001). Individuals who met NCCN testing criteria for HBOC or LS based on personal cancer history and reported history of cancer in first-degree relatives were more likely to carry a mutation than individuals who did not (P < .001).
Despite the last finding, 5 of 22 (22.7%) of mutation carriers did not meet NCCN testing guidelines. Table 5 provides the differences between carriers and noncarriers.
DISCUSSION
In this study, 18% of tested individuals with PC and a history of at least 1 other cancer that is associated with HBOC or LS were found to carry a mutation in a gene associated with PC risk. If prostate cancer is not included as a syndrome-related cancer, the mutation detection rate increases to 23%. Mutations were identified in 9 of 13 genes classically associated with PC. Mutations were also identified in BRIP1, CHEK2, and MUTYH, which have not been previously associated with PC. Individuals who had a previous history of more than 1 other cancer, individuals who met NCCN testing criteria, and individuals who underwent testing in a clinical rather than a research setting were more likely to carry a mutation in a PCrelated gene. The latter finding is not surprising given that, historically, an individual with PC who has undergone genetic testing would need to have a personal or family cancer history strongly suggestive of a hereditary predisposition to elicit referral for genetic testing. The reasons that more study participants did not have clinical genetic testing since they all had a history of at least 2 hereditary syndrome related cancers are unknown; it may be related to the fact that testing was simply not considered by their health care providers, because many individuals in this study were diagnosed with PC before the advent of multigene panel testing and the inclusion of genetic mutation status into PC treatment, or it may be related to the fact that previous cancer history is not currently incorporated into genetic testing guidelines for individuals with PC. Numerous other studies have reported the prevalence of germline mutations in cancer susceptibility genes in individuals with PC, many of which were performed in selected populations. Most of these studies were conducted before multigene panel testing became available and only investigated 1 or 2 genes, primarily BRCA1 and BRCA2 with a few studies reporting on CDKN2A, PALB2, and/or the mismatch repair genes. [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] Mutation prevalence ranged from 0% to 22% in these studies. Original Article
To our knowledge, 4 studies have estimated mutation prevalence based on multigene panel testing. Grant et al 37 reported that mutations were identified in 3.8% of unselected individuals with PC who underwent testing using a 13-gene PC-focused panel; mutations were detected in 10.7% and 11.1% individuals with a personal or family (first-degree relative) history of breast or colon cancer, respectively. Hu et al 38 reported on a cohort of unselected probands with PC who underwent genetic testing using a 21-gene general cancer panel; they found that 9.4% of their cohort had mutations identified in a PCrelated gene. Slavin et al 39 performed a retrospective study of 53 individuals with PC suspected to have a hereditary predisposition; next-generation sequencing of 706 candidate genes identified potentially contributory mutations in 16 study participants (30%), 7 of whom had a mutation in an established PC-related gene (13%). Shindo et al 40 found that 33 of 854 (3.9%) of individuals with apparently sporadic resected PC had a germline mutation identified through a 32-gene panel; 31 of these individuals (3.5%) had a mutation in a known PC gene. The 3 studies investigating unselected PC populations each reported mutations in PC-related genes in less than 10% of their participants. When accounting for personal and family history of breast and colon cancer, the mutation prevalence reported by Grant et al increased to more than 10%. The population studied by Slavin et al, which was selected given concern for a hereditary predisposition, also had a mutation prevalence of more than 10%. The mutation prevalence in our study participants, which was selected based on personal cancer history, was also more than 10%. Given that the entities that create guidelines for genetic testing have been reticent to embrace genetic testing for all individuals with PC, the results from our study suggest that a history of HBOC-or LS-related cancers sufficiently enriches the yield of genetic testing to be considered as an indication for genetic testing in individuals with PC.
The identification of mutations in MUTYH, CHEK2, and BRIP1 in our study raises the question of whether these genes may be previously unrecognized PC susceptibility genes or simply incidental findings. The MUTYH carrier frequency in the general white population is well documented to be 1-2%. 41, 42 In our study group, 2.6% of individuals with PC had a monoallelic MUTYH mutation. The prevalence of mutations in BRIP1 and CHEK2 is not as well established. A casecontrol study attempting to determine an association between BRIP1 mutations and breast cancer identified BRIP1 mutations in 2/2081 (0.096%) of controls. 43 In our study, 2 individuals were found to have BRIP1 mutations (1.3%), but 1 of them also had an MSH6 mutation. A case-control study involving women with breast cancer identified CHEK2 mutations in 6/459 (1.3%) of controls. 44 In our study, 2 individuals were found to have the CHEK2 p.I157T mutation (1.3%), recognizing that some participants whose testing included CHEK2 analysis were only tested for the 1100delC mutation.
Our study has certain limitations, some of which may have led to an underestimate of mutation prevalence. First, not all individuals in our registry with PC who had a history of another syndrome-related cancer had available DNA for research testing, so some individuals who did not have testing may carry a mutation. Second, the individuals in our study whose samples were sent for research testing did not have analysis of large deletions or duplications for any of the genes, nor did all individuals have complete sequencing of CHEK2 or PMS2, which almost certainly limited mutation detection rate for this group. While personal cancer history was verified with pathology reports or clinical medical records when possible (76/149 individuals), we had to rely on self-reporting for some individuals in the study, which may affect the accuracy of their medical history. For almost all cases, the presence or absence of cancer in first-degree relatives was based on patient self-reporting. Furthermore, most of the individuals in this study did not have a 3-generation pedigree collected by a genetic counselor, so information about broader family history was not included in our analysis. The lack of pedigrees to provide complete family history information precludes our ability to make conclusions about whether the family structures or extended family cancer histories were significantly different between PC gene mutation carriers and other study participants. Additionally, it should be acknowledged that our study population was selected based on personal cancer history and from a tertiary medical center with expertise in PC management, so these results are not generalizable to all individuals with PC. Finally, our statistical calculations consisted of univariate analysis of small subgroups of our study population, which should be taken into account when considering differences between PC gene mutation carriers and other study participants.
To our knowledge, this is the first report of mutation prevalence in individuals with PC who were selected for a personal history of other hereditary cancer syndromerelated cancers. Our results indicate that a history of cancer may enrich the yield of genetic testing, because a higher proportion of our study population carried mutations in PC-related genes than most previous reports. The importance of personal cancer history has already been incorporated into some other groups' recommendations for genetic testing. For example, Leachman et al 45 recently published an algorithm for considering genetic testing in individuals with melanoma; based on their scoring system, an individual with a personal history of both melanoma and PC is eligible for genetic testing because of the increased likelihood of a CDKN2A or BRCA2 mutation.
Given this study did not find a significant difference between mutation carriers and other study participants when considering smoking history and the fact that mutation carriers were more likely to be obese than other study participants suggest that the absence of lifestyle risk factors for PC is not a reliable predictor of mutation status and is not useful when constructing considerations for genetic testing. Although a younger age of diagnosis is sometimes used as a predictor of hereditary susceptibility for other cancer types (eg, breast and colon), our study showed no significant difference in age of PC diagnosis between mutation carriers and other individuals, suggesting that age at PC diagnosis does not need to be considered when developing genetic testing criteria. Finally, we found no significant differences between mutation carriers and other study participants when considering age at first cancer diagnosis or family history of LS-or HBOC-related cancers in first-degree relatives. This finding suggests that some of the factors accounted for in existing genetic testing guidelines (eg, age of breast cancer diagnosis or family history of cancer) may be poorer predictors of mutation status in individuals with PC than a personal history of LS-or HBOC-related cancers at any age.
Information about the genetic mutation status of individuals with PC has always provided useful information for their family members about cancer risk and prevention or early detection. Historically, however, clinical genetic testing has not been pursued routinely for individuals with PC because it would not influence the proband's medical management and is therefore unlikely to be a service covered by insurance. Consequently, guidelines for consideration of genetic testing for individuals with PC have lagged behind guidelines for other cancer types, such as breast and colon cancer. In our study, 23% of individuals who have a mutation in a PC-related gene did not meet current NCCN testing guidelines for HBOC or LS based on their personal history of cancer or the reported family history of cancer in first-degree relatives.
